Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism

Katalin Megyeri, Bernadett Marko, Nora Sziray, Istvan Gacsalyi, Zsolt Juranyi, Gyorgy Levay, L. Hársing

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although levodopa is the current "gold standard" for treatment of Parkinson's disease, there has been disputation on whether AMPA receptor antagonists can be used as adjuvant therapy to improve the effects of levodopa. Systemic administration of levodopa, the precursor of dopamine, increases brain dopamine turnover rate and this elevated turnover is believed to be essential for successful treatment of Parkinson's disease. However, long-term treatment of patients with levodopa often leads to development of dyskinesia. Therefore, drugs that feature potentiation of dopamine turnover rate and are able to reduce daily levodopa dosages might be used as adjuvant in the treatment of patients suffering from Parkinson's disease. To investigate such combined treatment, we have examined the effects of two non-competitive AMPA receptor antagonists, GYKI-52466 and GYKI-53405, alone or in combination with levodopa on dopamine turnover rate in 6-hydroxydopamine-lesioned striatum of the rat. We found here that repeated administration of levodopa, added with the peripheral DOPA decarboxylase inhibitor carbidopa, increased dopamine turnover rate after lesioning the striatum with 6-hydroxydopamine. Moreover, combination of levodopa with GYKI-52466 or GYKI-53405 further increased dopamine turnover enhanced by levodopa administration while the AMPA receptor antagonists by themselves failed to influence striatal dopamine turnover. We concluded from the present data that potentiation observed between levodopa and AMPA receptor antagonists may reflect levodopa-sparing effects in clinical treatment indicating the therapeutic potential of such combination in the management of Parkinson's disease.

Original languageEnglish
Pages (from-to)501-507
Number of pages7
JournalBrain Research Bulletin
Volume71
Issue number5
DOIs
Publication statusPublished - Mar 15 2007

Fingerprint

AMPA Receptors
Dopamine Antagonists
Parkinsonian Disorders
Levodopa
GABA-A Receptors
Dopamine
GYKI 53405
Parkinson Disease
Oxidopamine
Therapeutics
Drug Synergism
Carbidopa
Corpus Striatum
Dyskinesias

Keywords

  • 6-OHDA-lesioned striatum
  • AMPA antagonists
  • Dopaminergic neurotransmission
  • GABAergic projection neurons
  • Levodopa
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism. / Megyeri, Katalin; Marko, Bernadett; Sziray, Nora; Gacsalyi, Istvan; Juranyi, Zsolt; Levay, Gyorgy; Hársing, L.

In: Brain Research Bulletin, Vol. 71, No. 5, 15.03.2007, p. 501-507.

Research output: Contribution to journalArticle

Megyeri, Katalin ; Marko, Bernadett ; Sziray, Nora ; Gacsalyi, Istvan ; Juranyi, Zsolt ; Levay, Gyorgy ; Hársing, L. / Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism. In: Brain Research Bulletin. 2007 ; Vol. 71, No. 5. pp. 501-507.
@article{6015eaacc743488a8f23dfefda2d2762,
title = "Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism",
abstract = "Although levodopa is the current {"}gold standard{"} for treatment of Parkinson's disease, there has been disputation on whether AMPA receptor antagonists can be used as adjuvant therapy to improve the effects of levodopa. Systemic administration of levodopa, the precursor of dopamine, increases brain dopamine turnover rate and this elevated turnover is believed to be essential for successful treatment of Parkinson's disease. However, long-term treatment of patients with levodopa often leads to development of dyskinesia. Therefore, drugs that feature potentiation of dopamine turnover rate and are able to reduce daily levodopa dosages might be used as adjuvant in the treatment of patients suffering from Parkinson's disease. To investigate such combined treatment, we have examined the effects of two non-competitive AMPA receptor antagonists, GYKI-52466 and GYKI-53405, alone or in combination with levodopa on dopamine turnover rate in 6-hydroxydopamine-lesioned striatum of the rat. We found here that repeated administration of levodopa, added with the peripheral DOPA decarboxylase inhibitor carbidopa, increased dopamine turnover rate after lesioning the striatum with 6-hydroxydopamine. Moreover, combination of levodopa with GYKI-52466 or GYKI-53405 further increased dopamine turnover enhanced by levodopa administration while the AMPA receptor antagonists by themselves failed to influence striatal dopamine turnover. We concluded from the present data that potentiation observed between levodopa and AMPA receptor antagonists may reflect levodopa-sparing effects in clinical treatment indicating the therapeutic potential of such combination in the management of Parkinson's disease.",
keywords = "6-OHDA-lesioned striatum, AMPA antagonists, Dopaminergic neurotransmission, GABAergic projection neurons, Levodopa, Parkinson's disease",
author = "Katalin Megyeri and Bernadett Marko and Nora Sziray and Istvan Gacsalyi and Zsolt Juranyi and Gyorgy Levay and L. H{\'a}rsing",
year = "2007",
month = "3",
day = "15",
doi = "10.1016/j.brainresbull.2006.11.003",
language = "English",
volume = "71",
pages = "501--507",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism

AU - Megyeri, Katalin

AU - Marko, Bernadett

AU - Sziray, Nora

AU - Gacsalyi, Istvan

AU - Juranyi, Zsolt

AU - Levay, Gyorgy

AU - Hársing, L.

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Although levodopa is the current "gold standard" for treatment of Parkinson's disease, there has been disputation on whether AMPA receptor antagonists can be used as adjuvant therapy to improve the effects of levodopa. Systemic administration of levodopa, the precursor of dopamine, increases brain dopamine turnover rate and this elevated turnover is believed to be essential for successful treatment of Parkinson's disease. However, long-term treatment of patients with levodopa often leads to development of dyskinesia. Therefore, drugs that feature potentiation of dopamine turnover rate and are able to reduce daily levodopa dosages might be used as adjuvant in the treatment of patients suffering from Parkinson's disease. To investigate such combined treatment, we have examined the effects of two non-competitive AMPA receptor antagonists, GYKI-52466 and GYKI-53405, alone or in combination with levodopa on dopamine turnover rate in 6-hydroxydopamine-lesioned striatum of the rat. We found here that repeated administration of levodopa, added with the peripheral DOPA decarboxylase inhibitor carbidopa, increased dopamine turnover rate after lesioning the striatum with 6-hydroxydopamine. Moreover, combination of levodopa with GYKI-52466 or GYKI-53405 further increased dopamine turnover enhanced by levodopa administration while the AMPA receptor antagonists by themselves failed to influence striatal dopamine turnover. We concluded from the present data that potentiation observed between levodopa and AMPA receptor antagonists may reflect levodopa-sparing effects in clinical treatment indicating the therapeutic potential of such combination in the management of Parkinson's disease.

AB - Although levodopa is the current "gold standard" for treatment of Parkinson's disease, there has been disputation on whether AMPA receptor antagonists can be used as adjuvant therapy to improve the effects of levodopa. Systemic administration of levodopa, the precursor of dopamine, increases brain dopamine turnover rate and this elevated turnover is believed to be essential for successful treatment of Parkinson's disease. However, long-term treatment of patients with levodopa often leads to development of dyskinesia. Therefore, drugs that feature potentiation of dopamine turnover rate and are able to reduce daily levodopa dosages might be used as adjuvant in the treatment of patients suffering from Parkinson's disease. To investigate such combined treatment, we have examined the effects of two non-competitive AMPA receptor antagonists, GYKI-52466 and GYKI-53405, alone or in combination with levodopa on dopamine turnover rate in 6-hydroxydopamine-lesioned striatum of the rat. We found here that repeated administration of levodopa, added with the peripheral DOPA decarboxylase inhibitor carbidopa, increased dopamine turnover rate after lesioning the striatum with 6-hydroxydopamine. Moreover, combination of levodopa with GYKI-52466 or GYKI-53405 further increased dopamine turnover enhanced by levodopa administration while the AMPA receptor antagonists by themselves failed to influence striatal dopamine turnover. We concluded from the present data that potentiation observed between levodopa and AMPA receptor antagonists may reflect levodopa-sparing effects in clinical treatment indicating the therapeutic potential of such combination in the management of Parkinson's disease.

KW - 6-OHDA-lesioned striatum

KW - AMPA antagonists

KW - Dopaminergic neurotransmission

KW - GABAergic projection neurons

KW - Levodopa

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=33846447144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846447144&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2006.11.003

DO - 10.1016/j.brainresbull.2006.11.003

M3 - Article

C2 - 17259019

AN - SCOPUS:33846447144

VL - 71

SP - 501

EP - 507

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 5

ER -